Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer
Stephanie K. Bunt(University of Nebraska Medical Center), Ashley M. Mohr(University of Nebraska Medical Center), Jennifer M. Bailey(University of Nebraska Medical Center), Paul M. Grandgenett(University of Nebraska Medical Center), Michael A. Hollingsworth(University of Nebraska Medical Center)
Cited by 62Open Access
Abstract
Related Papers
A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma
George D. Demetri, Christopher D.�M. Fletcher, Elisabetta Mueller et al.|Proceedings of the National Academy of Sciences|1999|491